The Role of Glycemic Control and Vitamin D3 Levels in Modulating mRNA Expression of GLUT4 and IL-6 in Newly Diagnosed Type 2 Diabetes Mellitus Patients
Diabetes Mellitus
Abstract
Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and chronic low-grade inflammation. The molecular mechanisms of glucose transport and inflammation in T2DM are influenced by both glycemic status and vitamin D3 levels, particularly through their effects on GLUT4 and interleukin-6 (IL-6) expression. Methods: This cross-sectional study involved 34 newly diagnosed male T2DM patients aged 40–60 years. Glycated hemoglobin (HbA1c), serum 25(OH)D3, and IL-6 levels were measured using ELISA, and mRNA expression of GLUT4 was assessed by RT-qPCR. Correlation analysis and path analysis (PLS-SEM) were performed to evaluate the direct and indirect relationships among variables. Results: HbA1c levels showed a significant negative correlation with GLUT4 expression (r = –0.711, p < 0.001) and a positive correlation with IL-6 levels (r = 0.747, p < 0.001). Vitamin D3 levels mediated the effect of glycemic control on both IL-6 and GLUT4, with significant indirect effects observed (p < 0.05). Path analysis revealed that vitamin D3 partially mediated the relationship between HbA1c and molecular markers of inflammation and glucose transport. Conclusion: Poor glycemic control is associated with increased IL-6 and decreased GLUT4 expression in newly diagnosed T2DM patients. Vitamin D3 plays a mediating role in this mechanism and may serve as a therapeutic adjunct to modulate inflammation and glucose transport at the molecular level. These findings highlight the metabolic significance of vitamin D beyond bone health, particularly in the early management of T2DM.
Downloads
Metrics
References
World Health Organization. Global report on diabetes. Geneva: WHO; 2023.
International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: IDF; 2021.
Webber L. Global burden of diabetes: Current status and future projections. Lancet Diabetes Endocrinol. 2021.
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and predicted trends. J Epidemiol Glob Health. 2020;10(1):107–111.
Rajeev Goyal, Ishwarlal Jialal. Diabetes Mellitus Type 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
Muhammad N. The role of insulin resistance on GLUT4 translocation in type 2 DM patients. J Med Sci. 2018;20(2):55–62.
Sakinah N. Correlation of vitamin D with insulin resistance in the elderly. J Med Clin. 2017;3(2):22–28.
Carrillo-Larco RM, Barengo NC, Albitres-Flores L, Bernabe-Ortiz A. The diagnosis of type 2 diabetes in low and middle-income countries: A systematic review. Diabetes Med. 2019;36(6):716–725.
Sapra A, Bhandari P. Diabetes Mellitus. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
Eckstein ML, Williams DM, Smith AC, et al. Optimal management of type 2 diabetes. Diabetol Metab Syndr. 2019;11:48 .
Soelistijo SA, et al. Consensus on Management and Prevention of Type 2 Diabetes Mellitus in Indonesia. PERKENI; 2021.
Manna P, Jain SK. 1,25(OH)2D3 upregulates glucose transporter-4 and glucose utilization in 3T3L1 adipocytes. J Biol Chem. 2012;287(10):7655–7663.
Rehman K, Akash MSH, Liaqat A. Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr. 2017;27(3):229–236.
Sanda S, Adhikari P, Shrestha A, et al. Relationship between vitamin D deficiency and insulin resistance in newly diagnosed type 2 diabetes mellitus. Nepal Med Coll J. 2019;21(1):5–9.
Abudawood M, Al-Anazi WA, Al-Banawy NA, et al. Assessment of gender-related differences in vitamin D levels and cardiovascular risk factors in Saudi patients with type 2 diabetes mellitus. Saudi Med J. 2018;39(7):665–671.
Khudayar M, et al. The association between deficiency of vitamin D and diabetes mellitus type 2 (T2DM). Cureus. 2022;14(5 ):e 24878.
Upreti V, Maitra A, Ghosh S, et al. Effect of oral vitamin D supplementation on glycemic control in patients with type 2 diabetes mellitus with coexisting hypovitaminosis D: A parallel group placebo controlled randomized pilot study. Diabetes Metab Syndr. 2018;12(5):767–771.
Zhang Y, Leung DY, Richers BN, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012;188(5):2127–2135.
Aridan A. The relationship between vitamin D deficiency and interleukin 6 levels in obese children. Pediatrics. 2021;23(1):14–19.
Kampmann U, Mosekilde L, Juhl C, et al. Effects of 12 weeks of vitamin D3 treatment on insulin secretion, insulin sensitivity, and inflammation in type 2 diabetes: A double-blind, randomized, placebo-controlled trial. Eur J Endocrinol. 2014;171(5):527–535.
Rahmi A, Machrina Y, Yamamoto Y. GLUT4 expression and insulin sensitivity in skeletal muscle of type 2 diabetes mellitus patients. J Clin Transl Endocrinol. 2021;25:100262 .
Vargas D, Podder A, Sepulveda M. Role of GLUT4 in glucose homeostasis and insulin resistance: A mechanistic insight. Mol Metab. 2023;67:101625 .
Szymczak-Pajor I, Drzewoski J, Śliwińska A. The molecular mechanisms of vitamin D on insulin resistance and secretion. Nutrients. 2020;12(5):1354.
Wimalawansa SJ. Vitamin D deficiency: Effects on oxidative stress, epigenetics, gene regulation, and aging. Biomolecules. 2018;8(2):30.
Mohd Ghozali F, Giribabu N, Salleh N. Vitamin D3 improves GLUT4 translocation and expression in insulin-resistant skeletal muscle. Horm Mol Biol Clin Investig. 2022;43(3 ):e 2234.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Imam Fatkhurrohman, Andi Makbul Aman, Husaini Umar, Agussalim Bukhari, Heri Nugroho HS, Himawan Sanusi, Mochammad Hatta, Andi Alfian Zainuddin
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
